Table 1.
Baseline data of LUAD patients according to the expression and proportion of the K-Ras4A isoform
| Clinical parameters | Values | All patients | K-Ras4A expressiona | K-Ras4A proportionb | ||||
|---|---|---|---|---|---|---|---|---|
| N (%) | High [N (%)] | Low [N (%)] | p-valuec | High [N (%)] | Low [N (%)] | p-value | ||
| Age | ≥65 | 276 (53.5) | 137 (26.6) | 139 (26.9) | 1.0 | 141 (27.3) | 135 (26.2) | 0.616 |
| < 65 | 221 (42.8) | 110 (21.3) | 111 (21.5) | 107 (20.7) | 114 (22.1) | |||
| NAd | 19 (3.7) | 11 (2.1) | 8 (1.6) | 10 (1.9) | 9 (1.9) | |||
| Gender | Male | 238 (46.1) | 119 (23.1) | 119 (23.1) | 1.0 | 117 (22.7) | 121 (23.4) | 0.791 |
| Female | 278 (53.9) | 139 (26.9) | 139 (26.9) | 141 (27.3) | 137 (26.6) | |||
| Smoking history | Yes | 427 (82.8) | 219 (42.4) | 208 (40.3) | 0.299 | 215 (41.7) | 212 (41.1) | 1.0 |
| No | 75 (14.5) | 33 (6.4) | 42 (8.1) | 38 (7.4) | 37 (7.2) | |||
| NA | 14 (2.7) | 6 (1.2) | 8 (1.6) | 5 (1.0) | 9 (1.7) | |||
| KRAS amplificatione | Present | 61 (11.8) | 42 (8.1) | 19 (3.7) | 2.70E-3 | 30 (5.8) | 31 (6.0) | 1.0 |
| Absent | 455 (88.2) | 216 (41.9) | 239 (46.3) | 228 (44.2) | 227 (44.0) | |||
| KRAS mutations | Present | 148 (28.7) | 110 (21.3) | 38 (7.4) | 4.82E-12 | 101 (19.6) | 47 (9.1) | 2.49E-7 |
| Absent | 368 (71.3) | 148 (28.7) | 220 (42.6) | 157 (30.4) | 211 (40.9) | |||
| EGFR mutations | Present | 45 (8.7) | 12 (2.3) | 33 (6.4) | 1.81E-3 | 14 (2.7) | 31 (6.0) | 0.0125 |
| Absent | 471 (91.3) | 246 (47.7) | 225 (43.6) | 244 (47.3) | 227 (44.0) | |||
| Pathological stage | I | 276 (53.5) | 125 (24.2) | 151 (29.3) | 0.0460 | 128 (24.8) | 148 (28.7) | 0.0327 |
| II | 122 (23.6) | 66 (12.8) | 56 (10.9) | 58 (11.2) | 64 (12.4) | |||
| III | 84 (16.3) | 52 (10.1) | 32 (6.2) | 54 (10.5) | 30 (5.8) | |||
| IV | 26 (5.0) | 13 (2.5) | 13 (2.5) | 14 (2.7) | 12 (2.3) | |||
| NA | 8 (1.6) | 2 (0.4) | 6 (1.2) | 4 (0.8) | 4 (0.8) | |||
aMedian value (3.41 TPM) of K-Ras4A expression levels was used to divide LUAD patients into two groups
bMedian value (0.1659) of K-Ras4A proportions was used to divide LUAD patients into two groups
cChi square tests were used to examine the relationship between the nominal variables
dNA, Not available
eThe presence or absence of KRAS amplification were defined to 10% or more KRAS amplified or not